| American Bankers Insurance Association 
        May 28, 2004 Jennifer J. Johnson, SecretaryBoard of Governors of the
 Federal Reserve System
 20th Street and Constitution Ave., NW
 Washington, DC 20551
 Docket Number R-1188
 Office of the Comptroller of the Currency 250 E Street, SW
 Public Information Room, Mail Stop 1-5
 Washington, DC 20219
 Docket Number 04-09
 
 Robert E. Feldman, Executive Secretary Attention: Comments
 Federal Deposit Insurance Corporation
 550 17th Street, NW
 Washington, DC 20429
 RIN 3064-AC81
 Regulation Comments Chief Counsel's Office
 Office of Thrift Supervision
 1700 G St., NW
 Washington, DC 20552
 Attention: No. 2004-16
 
 Ms. Becky BakerSecretary of the Board
 National Credit Union Administration
 1775 Duke Street
 Alexandria, VA 22314-3428
 Dear Sir or Madam:  On behalf of the American Bankers Insurance Association and an 
        informal coalition of depository institutions and insurers that either 
        offer or administer debt cancellation contracts (DCCs) and debt 
        suspension agreements (DSAs), we appreciate the opportunity to comment 
        on the proposed regulations implementing section 411 of the Fair and 
        Accurate Credit Transactions Act of 2003 (FACT Act).  This comment letter primarily addresses the treatment of DCCs and 
        DSAs under the proposed regulation. As explained in detail below, we 
        respectfully recommend that such contracts and agreements be subject to 
        a specific exception to the prohibition on the use of medical 
        information rather than an interpretation of what constitutes 
        “eligibility for credit.” Such an exception not only is consistent with 
        the FACT Act and the legislative history of the Act, but also eliminates 
        the operational and legal uncertainties associated with the proposed 
        regulation.  Treatment of DCCs and DSAs  Our Proposed Exception  The proposed regulation interprets the phrase “eligibility, or 
        continued eligibility, for credit” to exclude determinations of whether 
        provisions of a DCC or DSA are triggered. In effect, this permits 
        creditors to consider medical information when deciding whether or not a 
        borrower is eligible for the protection afforded by a DCC or DSA. Such 
        an exclusion is particularly important in the case of DCCs and DSAs that 
        have triggering events related to the health of a borrower. Many DCCs 
        and DSAs provide credit protection in the event that a borrower becomes 
        disabled or dies. Access to medical information in that context is 
        necessary and appropriate to the operation of the DCC and DSA. Without 
        such information, it would be impossible to determine whether or not a 
        borrower was entitled to receive the protection promised in the DCC or 
        DSA.  On the other hand, the proposed interpretation fails to address all 
        circumstances in which medical information may be considered in 
        connection with a DCC or DSA and creates some legal uncertainty 
        regarding the application of the regulation to these products. 
        Therefore, we respectfully recommend that proposed Section __.30(d) be 
        revised to include the following specific exception for DCCs and DSAs:
         
(d)(1)(viii) To determine the eligibility for, the triggering of, or 
        the reactivation of a debt cancellation contract or debt suspension 
        agreement.  The Interpretation in the Proposed Regulation is Too Narrow 
 Our proposed exception is broader than the interpretation contained 
        in the proposed regulation. The interpretation in the proposed 
        regulation relates only to the determination of whether a DCC or DSA has 
        been triggered by an event specified in the DCC or DSA. While, as noted 
        above, medical information is a necessary and appropriate consideration 
        in such circumstances, medical information also is necessary and 
        appropriate in determining whether an individual is eligible to purchase 
        a DCC or DSA and whether such a contract or agreement should be 
        reactivated.  Creditors that sell DCCs and DSAs that include triggering events 
        related to the death or disability of a borrower frequently ask simple 
        “health” questions as part of the application process. Depending upon a 
        borrower’s response to a question, the creditor may decide not to offer 
        the borrower the DCC or DSA. Such questions are a necessary and 
        appropriate part of the sale of a DCC or DSA because they give a 
        creditor some control over the amount of risk they assume under the DCC 
        or DSA. They also permit the creditor to lower the price of the DCC or 
        DSA. Absent the ability to ask medical questions in connection with 
        offering a DCC or DSA that includes death or disability protection, the 
        price of such protection would, in many cases, be higher for all 
        borrowers.  Additionally, most DCCs and DSAs provide for the temporary suspension 
        and reactivation of the protection provided by the products if a 
        borrower falls behind in the payments due on the extension of credit 
        associated with the DCC and DSA and then brings those payments current. 
        Just as medical information is necessary and appropriate in determining 
        the initial eligibility for a borrower, it is equally necessary and 
        appropriate in making a reactivation determination.  The Interpretation in the Proposed Regulation Creates Legal 
        Uncertainty  Our proposed exception avoids the legal uncertainty created by the 
        proposed interpretation. The proposed interpretation creates legal 
        uncertainty because the preamble to the proposed rule provides no 
        rationale for the interpretation. This permits others to question, and 
        even challenge, the basis for the interpretation. More importantly, the 
        proposed interpretation calls into question the prevailing legal 
        classification of DCCs and DSAs. The prevailing legal view of DCCs and 
        DSAs is that such contracts and agreements are nothing more than a term 
        of an extension of credit. This treatment of DCCs and DSAs is reflected 
        in a debt cancellation regulation issued by the Office of the 
        Comptroller of the Currency1, an interpretation issued by the Chief 
        Counsel of the Office of Thrift Supervision2, and a regulation issued by 
        the National Credit Union Administration3. An interpretation that a 
        borrower’s eligibility for credit does not include a determination of 
        whether the provisions of a DCC or DSA are triggered could be read by 
        state insurance regulators to suggest that DCCs and DSAs are somehow 
        separate and distinct from the credit transaction. While presumably 
        unintended, such an outcome would be contrary to the rationale upon 
        which the existing DCC and DSA regulations and interpretation, cited 
        above, are based.  The Terms and Legislative History of the FACT Act Support Our 
        Proposed Exception  Our proposed exception is consistent with the terms of Section 411 of 
        the FACT Act. New Section 604(g)(5)(A) of the Fair Credit Reporting Act 
        (as added by Section 411) expressly empowers the federal banking 
        agencies and the National Credit Union Administration to except from the 
        prohibition on the use of medical information transactions that are 
        “necessary and appropriate to protect the legitimate operational, 
        transactional, risk, consumer, and other needs.” An exception for 
        determining the eligibility for, the triggering of, and the reactivation 
        of DCCs and DSAs falls within the ambit of this authority. As noted 
        above, the consideration of medical information in such contexts is 
        necessary and appropriate to the ability to provide borrowers with 
        promised protection (triggering and reactivation), and control the risk 
        and price of DCCs and DSAs (eligibility).  Our proposed exception also is supported by the legislative history 
        accompanying the FACT Act. The House Report accompanying the Act (House 
        Report 108-263) specifically states that the use of medical information 
        in connection with “credit-related debt cancellation agreements” is 
        “necessary and appropriate use of medical information”:  
The Committee recognizes that there are limited circumstances in 
          which a creditor may require medical information in determining a 
          consumer’s eligibility or continued eligibility for credit, for 
          example, to confirm the use of loan proceeds in connection with loans 
          to finance a specific medical procedure or device, or to verify a 
          consumer’s death or disability in connection with credit-related debt 
          cancellation agreements, and considers the limited use of medical 
          information in these circumstances and any similar circumstances the 
          financial regulators may identify, to be a necessary and appropriate 
          use of medical information for purposes of this section. (at page 53) While the foregoing statement is limited to the verification of a 
        death or disability, a section-by-section analysis of the Act introduced 
        in the Congressional Record of December 8, 2003 by the Chairman 
        of the House Financial Services Committee and the Chairman of the 
        Financial Institutions and Consumer Credit Subcommittee (who was an 
        original sponsor of the House version of the Act) indicates that 
        Congress did not intend any part of a DCC or DSA transaction to be 
        subject to the prohibition on the use of medical information:  
The Federal banking agencies and the NCUA are directed to prescribe 
          regulations that are necessary and appropriate to protect legitimate 
          business needs with respect to the use of medical information in the 
          credit granting process, including allowing appropriate sharing for 
          verifying certain transactions as well as for debt cancellation 
          contracts, debt suspension agreements, and credit insurance that are 
          not generally intended to be restricted by this provision. (at 
          page E2518) emphasis added  Treatment of Credit Insurance  The proposed interpretation of the phrase “eligibility, or continued 
        eligibility, for credit” applies not only to DCCs and DSAs, but also to 
        credit insurance. We respectfully recommend that the regulation be 
        revised to include a specific exception for credit insurance.  Technically, it is our opinion that Section 411(a) of the FACT Act 
        does not apply to credit insurance. Section 411(a) applies to credit 
        products, and, unlike DCCs and DSAs, credit insurance is not a credit 
        product; it is an insurance product. Nonetheless, the legislative 
        history cited above suggests that Section 411(a) may apply to credit 
        insurance. Therefore, we urge that the regulation remove any doubt 
        regarding the impact of Section 411(a) and specifically except credit 
        insurance from the scope of the regulation. The rationale for such an 
        exception is identical to the rationale for the exception for DCCs and 
        DSAs. Credit insurance frequently is associated with the death and 
        disability of a borrower, and consideration of the medical information 
        related to the borrower is necessary and appropriate to the operation of 
        credit insurance.  Conclusion  In conclusion, we urge the establishment of a specific exception for 
        all aspects of DCC and DSA transactions. Such an exception not only is 
        consistent with the FACT Act and the legislative history of the Act, but 
        also eliminates the operational and legal uncertainties associated with 
        the proposed regulation. We also urge that the regulation include a 
        specific exception for credit insurance. We appreciate the opportunity 
        to provide these comments.  Sincerely, 
 
 James C. Sivon   Barnett & Sivon, P.C.
 
 James T. McIntyre
 McIntyre Law Firm, PLLC
 
 Beth L. Climo
 Executive Director
 American Bankers Insurance Association
 
 
1 12 CFR Part 37. 2 Letter from Carolyn Lieberman, Acting Chief Counsel dated September 15, 1993
 3 12 CFR 721.3(g)
 
 |